Retinoic acid (RA) acts as an anti-proliferative and redifferentiation agent in the therapy of thyroid carcinoma. Our previous studies demonstrated that pretreatment of follicular thyroid carcinoma cell lines FTC-133 and FTC-238 resulted in decreased in vitro proliferation rates and reduced tumor cell growth of xenotransplants. In addition to the previous results, we found that RA led to decreased vitality and invasiveness of FTC-133 and FTC-238 cells as they reacted with reduction of intracellular ATP levels and number of migrated cells respectively. However, the molecular mechanisms by which RA mediates these effects are not well understood. Two-dimensional (2D) screening of the proteins related to ATP metabolism and western blot analysis revealed a-enolase (ENO1) to be down-regulated in FTC-133 and FTC-238 cells after RA treatment. 2D gel detection and mass spectrometric analysis revealed that ENO1 existed as three separate protein spots of distinct pIs (ENO1-A1-A3). Comparative 2D difference gel electrophoresis analysis of fluorescently labeled protein samples of RA-treated and untreated FTC-133 demonstrated a selective down-regulation of ENO1-A1 which we identified as a phosphoprotein. RA caused the dephosphorylation of ENO1-A1. Both, RA-mediated and specific knock-down of ENO1/MBP-1 resulted in the reduction of MYC oncoprotein, and simultaneously decreased proliferation rates of FTC-133 and FTC-238 cell lines. In summary, the RA-mediated down-regulation of the ENO1 gene products and MYC oncoprotein provides a novel molecular mechanism facilitating the anti-proliferative effect of RA in human thyroid carcinoma cells and suggests new pathways for supportive RA therapies.
Introduction
The vitamin A (retinol)-derived retinoic acids (RA) are important regulators of a diverse spectrum of physiological processes, including cell proliferation, differentiation, morphogenesis, angiogenesis, and apoptosis (Maden 2000 , Biesalski & Nohr 2003 , Buletic et al. 2006 . The pleiotropic effects of retinoids are mediated by a nuclear heterodimeric pair of retinoid receptors (RAR/RXR). Retinoid-activated RAR/RXR heterodimers mediate the transcription of specific gene networks, by binding to specific DNA response elements and recruiting cofactor complexes which cause the local chromatin structure to alter and engage the basal transcription machinery. RARs and RXRs also integrate a variety of signaling pathways through phosphorylation events which cooperate with the ligand for the control of retinoid-target genes transcription. Signaling cascades involve FOS, MAPK, PI3 kinase, AKT, cyclins, cyclin-dependent kinases and their inhibitors, Bcl proteins and caspases, all of which are involved in the control of cell growth, differentiation, and apoptosis (Niles 2000) . RA was successfully used for the treatment of hematological as well as therapy and chemoprevention of solid cancers (Hansen et al. 2000 , Lengfelder et al. 2005 including thyroid carcinomas (Simon et al. 2002) . Cell culture experiments in thyroid carcinoma cell lines showed that RA treatment affects thyroid-specific functions, cell-cell or cell-matrix interaction, differentiation markers, growth, and tumorigenicity (Schmutzler & Kohrle 2000) . RA has an antiproliferative effect on the follicular thyroid carcinoma cell lines FTC-133 and FTC-238. Furthermore, pretreatment of these cell lines with RA results in decreased in vitro proliferation rates and reduced tumor cell growth of xenotransplants (Schmutzler et al. 2004) .
Enolases are glycolytic enzymes responsible for the ATP-generating conversion of 2-phosphoglycerate to phosphoenolpyruvate. In vertebrates, there are three different tissue-specific isoenzymes: the a-enolase, ENO1, is expressed in a wide variety of tissues, whereas b-enolase is localized mainly in muscle and g-enolase is specific for neuronal tissues (Merkulova et al. 2000) . The ENO1 transcript encodes two structurally and functionally distinct proteins, a 48 kDa ENO1 enzyme and the 37 kDa MYC promotor-binding protein MBP-1. Enzymatic activity resides within the N-terminal portion, which is unique to ENO1 and absent in MBP-1 (Feo et al. 2000 , Subramanian & Miller 2000 , Pancholi 2001 ). Increased ENO1 gene activity and protein production have been detected in several carcinomas, including neuroendocrine tumors, neuroblastoma, lung cancer, hepatocellular carcinoma, and breast cancer cells, and suggest an involvement of ENO1 in tumor progression (Royds et al. 1982 , Kato et al. 1983 , Kaiser et al. 1989 , Ledermann 1994 , Niklinski & Furman 1995 , Redlitz et al. 1995 , Ebert et al. 1996 , Joseph et al. 1996 , Chang et al. 2003 , Takashima et al. 2005 , Zhang et al. 2005 , Huang et al. 2006 , Yoon et al. 2006 . The up-regulation of ENO1, glucose phosphate isomerase, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in thyroid oncocytoma tumors identifies ENO1 as a member of a metabolic signature in thyroid tumors (Baris et al. 2004) . The increased presence of ENO1 could result in accelerated ATP production and, thus, ENO1 may act as a metabolic tumor promoter conferring a selective growth advantage onto ENO1 overexpressing tumor cells.
Here we show that RA treatment of the human follicular thyroid carcinoma cell lines FTC-133 and FTC-238 causes the down-regulation of ENO1 and MBP-1 and this correlated with both reduction of cell invasiveness and the down-regulation of MYC oncoprotein. Moreover, we provide first evidence by two-dimensional (2D) gel electrophoresis and mass spectrometric analysis of an RA-induced alteration in ENO1 phosphorylation. 0 -AAT-TCT-CCG-AAC-GTG-TCA-CGT-3 0 not matching any known human gene served as a control. Transfection was done in the presence of OptiMem (Invitrogen) medium and analyses were performed after 72 h. All experiments were repeated at least three times.
Materials and methods

Motility assay
Motility of FTC-133 and FTC-238 cells pretreated with RA was evaluated in 24-well Transwell chambers (Costar, Bodenheim, Germany). The upper and lower culture compartments were separated by polycarbonate filters with 8 mm pore size. To investigate the effect of RA on the motility of differentiated thyroid carcinoma cells, FTC-133 or FTC-238 were pretreated with 1 mM RA (dissolved in ethanol) for 72 h and then plated at 1! 10 4 cells/well in DMEM/F12 medium without FCS. Control cells were pretreated with medium containing the same concentration of ethanol but without RA. The cells migrated from upper to lower compartment for 24 h in a 5% CO 2 atmosphere at 37 8C. After a 24-h motility period, cells remaining on top of the filter were wiped off with cotton swabs and those cells that had traversed the membrane pores to the lower surface of the membrane were washed with chilled PBS, incubated for 5 min in 1:1 PBS/methanol (Merck) and 15 min in methanol before staining with 0 . 1% toluidine blue (Merck) in 2 . 5% sodium carbonate (Roth, Karlsruhe, Germany). Migrated cells were counted by light microscopy (Zeiss, Jena, Germany) in four separate high-power fields per filter.
Western blot
About 20 mg total protein lysate from RA-stimulated and untreated FTC-133 and FTC-238 cells, and 200 mg (for 2D western blot) of total protein from wild-type FTC-133, were separated on 10% polyacrylamide gels and blotted on a PVDF membrane (Amersham Biosciences). Blocking was performed in 5% non-fat milk powder/1!TBST (Tris buffered saline/0 . 05% Tween20). After thrice washing with 1!TBST, membranes were incubated overnight with enolase C-19 polyclonal goat antiserum (1:10 000), MYC (1:1000) (both Santa Cruz Biotechnology, Santa Cruz, CA, USA) and b-actin (1:10 000, Sigma) in 1!TBST. Secondary anti-goat (1:50 000) and anti-mouse (1:20 000) antibodies were used (both Santa Cruz Biotechnology). Immunoreactive bands for ENO1, MBP-1, MYC, and b-actin were visualized using the ECL Detection Kit (Amersham Biosciences) and Kodak Image System 440cf (Eastman Kodak, Rochester, NY, USA).
Protein extraction and purification for 2D gel electrophoresis FTC-133 cells were washed twice with PBS prior to the protein extraction. Proteins were extracted using two different lysis buffers, a) a standard 2D lysis buffer was used for silver staining (8 M Urea, 4% CHAPS, 1% dithiothreitol (DTT), 0 . 8% Pharmalyte) and b) a 2D extraction buffer for use with fluorescent-labeled dyes (7 M Urea, 2 M Thiourea, 4% CHAPS, 2% Pharmalyte, 2% DTT). Cells were incubated with lysis buffers for 30 min at room temperature (RT) and further purified with the trichloroacetic acid (TCA)-based 2D Clean Up Kit (Amersham Biosciences). Purified proteins were dissolved in rehydration solution for use in silverstained gels (8 M Urea, 2% CHAPS, 0 . 5% Pharmalyte, 40 mM DTT) or fluorescent-labeled gels (8 M Urea, 1% CHAPS, 0 . 4% DTT, 0 . 4% Pharmalyte) and stored at K80 8C until use.
Two-dimensional gel electrophoresis
Isoelectric focusing (IEF, first dimension) was carried out on an IPGphor (Amersham Biosciences). Total protein (30 or 150 mg) was loaded onto nonlinear, 18 cm (pH 3-10) immobilized pH gradient (IPG) strips and rehydrated under low voltage conditions (30 V) for 12 h. For 2D fluorescence difference gel electrophoresis (DIGE), 30 mg total protein from RA-stimulated and untreated FTC-133 control were labeled with dyes Cy2 (blue, control) and Cy3 (green, RA-treated; Amersham Biosciences) respectively. Labeling reactions were incubated for 30 min on ice in the dark and stopped for 10 min with 10 mM lysine. Labeled proteins were combined at a 1:1 ratio, dissolved in rehydration solution, and IEF was performed at 8000 V for 9 h. IPG strips were equilibrated first in 10 ml equilibration solution (6 M urea, 2% SDS, 50 mM Tris-HCl (pH 8 . 8), 30% glycerol) with 100 mg DTT (Roth) for 15 min and in 10 ml equilibration solution with 250 mg iodoacetamide (IAA, Sigma) for another 15 min. Then IPG strips were arrested on a 12 . 5% polyacrylamide gel (37 . 5:1 Rothiphorese Gel 30, 10% SDS, 1 . 5 M Tris-HCl (pH 8 . 8), 10% APS, TEMED) using 0 . 5% agarose.
Second dimensional electrophoresis was performed in an Ettan Dalt Unit (Amersham Biosciences) using SDS electrophoresis buffer (Tris-base 25 mM, glycine 192 mM, SDS 0 . 1%) at 2 . 5W/gel for 30 min and at 5W/gel for the next 5-6 h. For silver staining, gels were fixed for 1 h in 40% ethanol, 10% acetic acid, washed 3!20 min in 30% ethanol, sensitized in 0 . 02% sodium thiosulfate, washed 3!20 s in distilled water (H 2 Odest). Staining was performed for 20 min with 0 . 25% silver nitrate, 0 . 00925% formaldehyde. Gels were washed 3!20 s in H 2 Odest, developed in 3% sodium carbonate, 0 . 0185% formaldehyde, washed 20 s in H 2 Odest, and the silver staining reaction was stopped after exactly 10 min in 5% acetic acid and 3!10 s washing in H 2 Odest. For semi-quantitative protein spot evaluation, silver stained gels were scanned using a visual light scanner Hewlet Packard scanjet 7400C and analyzed with Phoretix 2D software (Nonlinear Dynamics, Newcastle upon Tyne, UK). Fluorescently labeled protein gels were analyzed using the Typhoon scanner and the DeCyder pro software (Amersham Biosciences). Up-regulated proteins isolated from untreated FTC-133 and labeled with Cy2 appeared as blue spots. Up-regulated proteins from RA-treated FTC-133 labeled with Cy3 appeared as green spots. White, overlapped protein spots indicate no difference between control and RA-treated cells.
Protein preparation for mass spectrometry
Spots of interest (molecular range between 30 and 60 kDa) were excised from gels, chopped into cubes (w1 mm 3 ), and dried in a vacuum concentrator. For MALDI-ToF MS analysis, spots were destained with 100 mM potassium ferricyanide/30 mM sodium thiosulfate, washed with water (HPLC grade, Roth), shrunk with acetonitrile (ACN), and dried in a vacuum concentrator. The dried gel pieces were rehydrated with 30-50 ml cold trypsin solution (15 mg/ml). Digestion was performed for 16-24 h at 37 8C. Peptides were extracted twice with 50 ACN/5% trifluoroacetic acid (TFA) and dried. For Q-ToF-MS/MS analysis, protein spots were washed with water (HPLC grade, Roth), shrunk with acetonitrile, and dried. Proteins were reduced (100 mM DTT in 100 mM NH 4 HCO 3 ), alkylated (55 mM IAA in 100 mM NH 4 HCO 3 ), and digested with 12 . 5 ng/ml trypsin dissolved in 5 mM CaCl 2 /50 mM NH 4 HCO 3 . Peptides were extracted with ACN/5% formic acid and dried in a vacuum concentrator. Desalting was performed with ZipTip (Millipore Corporation, Billerica, MA, USA) containing C 18 reverse-phase medium. Peptides desalted for MALDIToF MS were dissolved in 50% ACN/0 . 1% TFA and for Q-ToF MS/MS in 70% methanol/1% formic acid.
Mass spectrometric analysis
MALDI-ToF MS identification of peptide mixtures was performed on a VoyagerDE Pro mass spectrometer (Applied Biosystems, Forester City, CA, USA). Dissolved peptides (50% ACN/0 . 1% TFA) were combined with matrix (a-cyano-4-hydroxy-trans-cinnamic acid) in a 1:1 ratio (vol:vol) and spotted onto the sample plate. Mass spectra were externally calibrated with Sequazyme Protein Digest Standards Kit (Applied Biosystems) containing des-Arg 1 -bradykinin, angiotensin I, Glu 1 -fibrinopeptide-B, neurotensin, b-galactosidase, and glycogen phosphorylase. Protein identification was performed using Mascot DataBase, where peptide mass tolerance was set to 100 ppm. One possible missed cleavage for trypsin digestion was allowed. Spectra were reconstructed with DataExplorer and analyzed with Mascot data bank.
MS/MS protein analyses were performed using the QSTAR Q-ToF mass spectrometer (Applied Biosystems) equipped with a nanospray source. External mass calibration in ToF mode was performed using synthetic sex determining octapeptide (Bachem AG, Bubendorf, Switzerland) combined with cesium iodide (Sigma) dissolved in a mixture of water/methanol/formic acid (49 . 5/49 . 5/1). For mass calibration in MS/MS mode, we used Glu-fibrinopeptide-B (Sigma) diluted in 30% methanol/1% formic acid. Protein identification, sequencing, and modification mapping were performed using BioAnalyst software and PepSea server (Applied Biosystems). Mass tolerance was set to 50 and 100 ppm and no missed cleavages for trypsin were allowed.
MTT and ATP assays
In 96-well plates, 5!10 3 FTC-133 and FTC-238 cells were seeded and cultured with DMEM-F12 medium without FCS. After 24 h, RA was added and cells were incubated for additional 24, 48, and 72 h. For MTT assay, cells were stained with MTT (3-[4, 5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) for 4 h at 37 8C. Colorimetric measurements were done with a Tecan Elisa Reader (Tecan, Grödig, Austria). For ATP assays, substrate (100 ml) was added to each well (CellTiter-Glo Luminescent, Promega) and incubated with the cells on a shaker and on the bench top for 2 min and 10 min respectively. Luminescence was measured with a Sirius luminometer (Berthold Detection Systems, Pforzheim, Germany). All experiments were done in triplicates.
Apoptosis assay
Control and RA-treated FTC-133 and FTC-238 cells were incubated with Annexin-V-Fluos staining kit (Roche). Annexin V is a Ca 2C -dependent phospholipid-binding protein with high affinity for phosphatidylserine (PS). Since both apoptotic and necrotic cells expose PS, simultaneous staining with propidium iodide was employed in order to discriminate between red necrotic and green labeled apoptotic cells. Evaluations were performed using Axioplan 2 fluorescent microscope and Axiovision software (Zeiss). Additionally expression of annexin V was evaluated by DIGE and mass spectrometric analysis.
Results
RA-induced decreased proliferation and motility of follicular thyroid carcinoma cell lines, but not apoptosis In order to investigate whether different thyroid carcinoma cell lines respond to RA treatment with altered proliferation, follicular thyroid carcinoma cells FTC-133 and FTC-238, and 8505C, C-643, Hth74, SW1736 representing undifferentiated thyroid carcinoma, were subjected to MTT assay. As shown in Fig. 1A , out of six cell lines analyzed, only FTC-133 and FTC-238 responded to RA treatment with significantly reduced proliferation rates. Other cell lines revealed only slightly changed proliferation profiles; however, the differences were not significant. Our further investigations were focused on differentiated thyroid cell lines FTC-133 and FTC-238 only. Previous experiments demonstrated decreased metabolic activity of both cell lines. To further verify whether RA actions are connected with reduced vitality and energy production, we measured intracellular ATP levels in these cell lines. Figure 1B demonstrates ATP assay performed by the evaluation of luminescence after 24, 48, and 72 h of RA treatment. Similar to MTT assay, also in this case, investigated cell lines responded to RA with significantly decreased vitality, especially visible after 72 h. To examine the effects of RA on invasiveness of FTC-133 and FTC-238, the cells pretreated with RA for 72 h were subjected to motility assays. As demonstrated in Fig. 2A , migrated control and RA-treated cells were stained and photographed using light microscopy (lower panel). Decreased number of migrated cells is visible on both RA-pretreated filters as compared with controls. Also cell counting revealed significantly reduced motility rates for both cell lines after RA pretreatment (upper panel). In order to examine whether observed RA effects could be due to apoptosis induction, control and RA-treated cells were stained with the apoptosis marker annexin V (Fig. 2B) . However, investigations performed by employing fluorescent microscopy revealed no noticeable differences in annexin V and propidium iodide staining. Both control and RA-treated cells revealed the presence of apoptotic and necrotic cells. Additionally, our observations were further supported by DIGE and mass spectrometric analysis. As shown in Fig. 3A , identification of annexin V revealed no significant differences between its expression in control and RAtreated cells, as it appeared as a white protein spot.
Two-dimensional analyses revealed RA involvement in alteration of FTC-133 proteome
To clarify previously observed effects of RA on differentiated thyroid carcinoma cell lines and possible molecular mechanisms, control and RA-treated FTC-133 cells were subjected to DIGE (Fig. 3A) . Automatic spot detection using DeCyder software was followed by filtering of spots in each gel. We found that out of 669 protein spots detected, RA treatment led to up-regulation of 1 and down-regulation of 8, while 660 protein spots remained unchanged. Mass spectrometric analysis revealed that out of eight protein spots down-regulated, two of them, ENO1 and GAPDH, are related to ATP metabolism and energy production, and were previously reported to be up-regulated in thyroid oncocytomas (Baris et al. 2004) . We found that both proteins exist as isoforms with differential pI values designated in case of ENO1 as A1, A2, and A3. The smaller 37 kDa MBP-1 protein is labeled as B1. In fluorescent staining experiments, MBP-1 production and ENO1 spots A2 and A3 showed no significant differences between RA-treated and control samples. However, RA caused a down-regulation of the ENO1 spot corresponding to A1, which is demonstrated by its increased blue fluorescence in control sample. We could also demonstrate that RA led to decrease in GAPDH production (spot G1). It is worth to notice that besides ENO1, also GAPDH belongs to the glycolytic pathway. RA-mediated dephosphorylation of ENO1 protein DIGE analysis revealed the presence of three distinct immunoreactive ENO1 proteins (A1, A2, and A3), which differed in their pI values. Additionally, RA treatment led to decreased expression of ENO1-A1 protein.
To answer the question whether the presence of differential ENO1 isoforms and decreased expression of ENO1-A1 protein are associated with post-translational modification, control and RA-treated silver-stained gels were analyzed by mass spectrometry. Excised ENO1-related protein spots were identified using MALDI-ToF and verified by MS/MS sequencing. Employing a specific antiserum used to detect ENO1 and MBP-1, ENO1-A1-3 and MBP-1-B1 protein spots were confirmed by 2D-western blot analysis (Fig. 3B) . MS/MS analysis and phosphorylation mapping demonstrated the RA-mediated dephosphorylation of ENO1-A1 protein spot. ENO-A1 was first identified in the ToF MS spectrum (Fig. 4A) . The ESI-MS/MS spectrum ( (Fig. 4C) . Other mass differences visible by comparison of both MS/MS spectra did not match any known modifications.
RA led to simultaneous down-regulation of ENO1, MYC, and MBP-1
Previous reports demonstrated that both ENO1 and MBP-1 proteins could act as transcriptional repressors of MYC (Feo et al. 2000) , and through the ability to regulate a significant number of genes, MYC itself is a key regulator of cell behavior. Additionally, many of MYC targeting pathways are deregulated in cancer cells and contribute to its enhanced expression (Vervoorts et al. 2006) . In order to clarify the relationship between RA-mediated down-regulation of ENO1 gene products and reduced proliferation rates of FTC-133 and FTC-238 cells, we performed western blotting. Incubation of total protein extracts obtained from both cell lines with specific ENO1 and MYC antibodies revealed that RA led to simultaneous down-regulation of all examined proteins, especially visible after 72 h of RA treatment ( Fig. 5A and B) .
Similar effects could be demonstrated after specific knock-down of ENO1. We found that employing siRNA targeting both ENO1 gene products led to decreased MYC levels accompanied by reduced proliferation rates of FTC-133 and FTC-238 cell lines (Fig. 6A and B) .
Discussion
The present study identified ENO1 and MBP-1 as a novel target molecules of RA action and demonstrated a direct involvement of ENO1 in the invasiveness of human thyroid carcinoma cells. Furthermore, we demonstrated for the first time three different ENO1 (A1-A3) isoforms and showed the selective dephosphorylation of ENO1-A1 residue Tyr 407 as a result of RA treatment in FTC-133 cells. RA caused a decrease in both ENO1 and MBP-1 total protein and this coincided with decreased MYC levels and reduced proliferation and motility of follicular thyroid carcinoma cell lines. ENO1 and MBP-1 are transcribed from a single transcript and share a common C-terminal MYC promotor-binding domain, but only ENO1 contains an enzymatically active N-terminal domain and, thus, displays enolase activity (Feo et al. 2000) . The up-regulation of glycolytic enzymes, including ENO1 and GAPDH, appears to be a common strategy in carcinoma of diverse origin, including thyroid oncocytoma (Baris et al. 2004) , suggesting a direct involvement of both enzymes in tumor growth. The impaired energy metabolism observed in FTC-133 and FTC-238 upon RA treatment likely reflected a reduction in GAPDH and a-enolase activity and impaired glycolytic activity. A detailed comparative analysis of the effect of RA treatment on different GAPDH and ENO1 isoforms revealed a selective down-regulation of GAPDH-G1 and ENO1-A1 as determined by fluorescent DIGE, implicating both proteins as executioners for the RAinduced suppressive metabolic effects in FTC-133. We found that RA-mediated decrease in the metabolic activity and proliferation of follicular thyroid carcinoma cell lines likely involved additional mechanisms. One such cellular event elicited by RA in FTC-133 and FTC-238 was the down-regulation of the common MYC promoter-binding domain present in both ENO1 and MBP-1 (Subramanian & Miller 2000) . This down-regulation of ENO1 and MBP-1 coincided with a decrease of MYC suggesting an oncogene suppressive effect by which RA can impair thyroid carcinoma growth. The same effects were observed after employing specific siRNA targeting ENO1 and MBP-1. Silencing of the MYC promoter-binding domain in both proteins also led to MYC down-regulation and reduced proliferation rates of FTC-133 and FTC-238 cell lines. However, MBP-1 has been largely described to act as a repressor of the MYC, but it seems that in follicular thyroid carcinoma, the bifunctional role of enolase is diminished and ENO1 possess the enzymatic activity only. Although there is no direct evidence of the regulation of a-enolase function by MYC, it is possible that a-enolase gene could be affected through its two perfect CACGTG MYC-MAX binding motifs. Previous studies demonstrated that up-regulation of glycolytic enzymes as well as glycolysis occurred as a consequence of MYC overexpression. It is suggested that increased energy production was due to the interaction of MYC with two imperfect CACGTG motifs in carbohydrate response element of pyruvate kinase. The promoter of a-enolase gene also contains CACGTC motifs and may act as MYC binding partner (Giallongo et al. 1990 , Towle 1995 .
The RA-induced down-regulation of MYC and resulting decrease in tumor cell proliferation is a common phenomenon described previously in lung cancer and myeloid cell lines (Kalemkerian et al. 1994 , Akie et al. 2000 , Dimberg et al. 2002 , Vervoorts et al. 2006 . However, information on the potential role of ENO1 and MBP-1 in these carcinoma entities is lacking.
The effect of RA on ENO1 was not restricted only to the down-regulation of the ENO1 protein, but also involved the RA-induced dephosphorylation of phosphor-Tyr 407 residue in ENO1-A1 as demonstrated by mass spectrometry. Single dephosphorylation events have been shown to affect protein function and reduce cell migration and angiogenesis (Moriyama et al. 1996 , Urbich et al. 2002 or increased apoptosis (Matsuoka et al. 2003) . However, as demonstrated by our experiments, RA-mediated dephosphorylation of ENO1 was not associated with induction of apoptosis. RA can act post-transcriptionally to regulate the half-life B TROJANOWICZ and others . RA down-regulates ENO1/MBP-1 gene products of cell cycle proteins (Sueoka et al. 1999) and has been known to modify the activity of proteins by affecting their phosphorylation status as demonstrated for the RARG (Gianni et al. 2002) . Although the functional consequences on the enzymatic or MYC promotorbinding activity of this single dephosphorylation event in ENO1-A1 remain elusive at present, our data suggested that dephosphorylated ENO1 was unable to compensate for the metabolic shortfall caused by RA.
RA therapy administrated for differentiated thyroid carcinoma is tolerated well with few side effects. We found that 1 mM (300 ng/l) RA used in our study led to reduced invasiveness of two follicular carcinoma cell lines, accompanied by a decrease in ENO1 and MYC production. This could be partially explained by reduced glucose metabolism and tumor size, previously observed as a favorable response to RA therapy (Simon et al. 1998) . Basal levels of natural RA (all trans) in human serum are in the range of 2-10 nM (Hong & Itri 1994) . Administration of synthetic or therapeutic levels of RA (e.g. 13 cis RA) frequently used in cancer such as leukemia (Huang et al. 1988 , Castaigne et al. 1990 or dermatology therapy (Verma 1987 ) easily reach the low micromolar levels (0 . 5-5 mM) depending on time, duration, and dose of treatment. In addition, various retinoid metabolites are formed in the low to high nanomolar range. Therefore, as demonstrated before (Fex et al. 1996 , Chanson et al. 2008 ), 1 mM concentrations of RA in human serum are easy to reach in therapeutic protocols.
In summary, we identified a 48 kDa translation product of ENO1 gene, as a novel target and executioner of the action of RA reducing the invasiveness of the human follicular thyroid carcinoma cell lines FTC-133 and FTC-238. RA-induced reduction of both the key glycolytic enzyme and proliferationpromoting MYC may serve as an additional predictive parameter of successful redifferentiation and antitumor therapy.
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